{"entity":{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","aka":["PRESERVE-004"],"tldr":"A phase 2 trial of Gotistobart, Pembrolizumab in ovarian cancer, run by OncoC4, Inc., active and no longer recruiting.","summary":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT05446298 by OncoC4, Inc., with 58 participants enrolled, started 2022-12-22 and due to reach its primary completion in 2026-08-30. Interventions recorded: ONC-392, Pembrolizumab. Conditions listed: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05446298","url":"https://clinicaltrials.gov/study/NCT05446298"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["gotistobart","pembrolizumab"],"companies":["oncoc4"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05446298","phase":"2","setting":"Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)","sponsor":"OncoC4, Inc.","started":"2022-12-22","startedType":"actual","enrolled":58,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05446298/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/"}]}}